cdi

CDIBA, an inhibitor of cytosolic phospholipase A2 (cPLA(2)), is utilized to study the role of cPLA(2) in tumor angiogenesis.

Fidaxomicin (Tiacumicin B) is a semisynthetic macrolide antibiotic used to treat Clostridium difficile-associated diarrhea in adults. Fidaxomicin has minimal systemic absorption and has not been linked to serum enzyme elevations during therapy or to instances of clinically apparent, acute liver injury.

N,N'-Carbonyldiimidazole is a biological cross-linking agent that has great application in mass spectrometry to detect the purity of compounds.

CRS3123 (REP-3123) dihydrochloride is an orally active, fully synthetic antimicrobial agent that effectively inhibits Clostridioides difficile methionyl-tRNA synthetase (MetRS). CRS3123 dihydrochloride can be used in the study of Clostridioides difficile infection (CDI).

CamA-IN-1 is a Clostridioides difficile -specific DNA adenine methyltransferase (CamA) inhibitor. CamA-IN-1 has inhibitory for CamA with IC 50 and K d values of 0.4 μM and 0.2 μM, respectively. CamA-IN-1 can be used for the research of Clostridioides difficile infections (CDI) .

Compound 158 (6c), a Micrococcin analogue, serves as an antibacterial agent effective against impetigo and Clostridium difficile infection (CDI) [1].

Compound 6d (Antibacterial agent 159) is an antibiotic effective against impetigo and Clostridium difficile infection (CDI), with no observed recurrence for CDI and minimal impact on the beneficial gut microbiome [1].